Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination;Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting local reactions;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting systemic events;In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting local reactions;In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting systemic events;In participants who receive a third dose of BNT162b2 as a result of current or anticipated recommendations, percentage of participants reporting adverse events;In participants who receive a third dose of BNT162b2 as a result of current or anticipated recommendations, percentage of participants reporting serious adverse events;In participants who receive a third dose of BNT162b2 as part of the subset for evaluation of boostability and protection against emerging VOCs, percentage of participants reporting adverse events;In participants who receive a third dose of BNT162b2 as part of the subset for evaluation of boostability and protection against emerging VOCs, percentage of participants reporting local reactions;In participants who receive a third dose of BNT162b2 as part of the subset for evaluation of boostability and protection against emerging VOCs, percentage of participants reporting serious adverse events;In participants who receive a third dose of BNT162b2 as part of the subset for evaluation of boostability and protection against emerging VOCs, percentage of participants reporting systemic events;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting adverse events;In participants, who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting local reactions;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting serious adverse events;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting systemic events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting local reactions;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting serious adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting systemic events;Noninferiority of the SARS-CoV-2 reference strain neutralizing titers after a third dose of BNT162b2 at 30 µg compared to after 2 doses of BNT162b2, in the same individuals;Noninferiority of the SARS-CoV-2 SA strain neutralizing titers after 2 doses of BNT162b2SA compared to the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2;Noninferiority of the SARS-CoV-2 SA strain neutralizing titers after one dose of BNT162b2SA compared to the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2, in the same individuals;Percentage of participants 12-15 years of age in Phase 3 reporting adverse events;Percentage of participants 12-15 years of age in Phase 3 reporting adverse events;Percentage of participants in Phase 1 reporting adverse events;Percentage of participants in Phase 1 reporting local reactions;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 2/3 reporting adverse events;Percentage of participants in Phase 2/3 reporting serious adverse events;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments

Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination;Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting local reactions;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting systemic events;In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting local reactions;In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting systemic events;In participants who receive a third dose of BNT162b2 as a result of current or anticipated recommendations, percentage of participants reporting adverse events;In participants who receive a third dose of BNT162b2 as a result of current or anticipated recommendations, percentage of participants reporting serious adverse events;In participants who receive a third dose of BNT162b2 as part of the subset for evaluation of boostability and protection against emerging VOCs, percentage of participants reporting adverse events;In participants who receive a third dose of BNT162b2 as part of the subset for evaluation of boostability and protection against emerging VOCs, percentage of participants reporting local reactions;In participants who receive a third dose of BNT162b2 as part of the subset for evaluation of boostability and protection against emerging VOCs, percentage of participants reporting serious adverse events;In participants who receive a third dose of BNT162b2 as part of the subset for evaluation of boostability and protection against emerging VOCs, percentage of participants reporting systemic events;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting adverse events;In participants, who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting local reactions;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting serious adverse events;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting systemic events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting local reactions;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting serious adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting systemic events;Noninferiority of the SARS-CoV-2 reference strain neutralizing titers after a third dose of BNT162b2 at 30 µg compared to after 2 doses of BNT162b2, in the same individuals;Noninferiority of the SARS-CoV-2 SA strain neutralizing titers after 2 doses of BNT162b2SA compared to the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2;Noninferiority of the SARS-CoV-2 SA strain neutralizing titers after one dose of BNT162b2SA compared to the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2, in the same individuals;Percentage of participants 12-15 years of age in Phase 3 reporting adverse events;Percentage of participants 12-15 years of age in Phase 3 reporting adverse events;Percentage of participants in Phase 1 reporting adverse events;Percentage of participants in Phase 1 reporting local reactions;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 2/3 reporting adverse events;Percentage of participants in Phase 2/3 reporting serious adverse events;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments

Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination;Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting local reactions;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting systemic events;In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting local reactions;In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting systemic events;In participants who receive a third dose of BNT162b2, percentage of participants reporting adverse events;In participants who receive a third dose of BNT162b2, percentage of participants reporting local reactions;In participants who receive a third dose of BNT162b2, percentage of participants reporting serious adverse events;In participants who receive a third dose of BNT162b2, percentage of participants reporting systemic events;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting adverse events;In participants, who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting local reactions;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting serious adverse events;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting systemic events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting local reactions;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting serious adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting systemic events;Noninferiority of the SARS-CoV-2 reference strain neutralizing titers after a third dose of BNT162b2 at 30 µg compared to after 2 doses of BNT162b2, in the same individuals;Noninferiority of the SARS-CoV-2 SA strain neutralizing titers after 2 doses of BNT162b2SA compared to the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2;Noninferiority of the SARS-CoV-2 SA strain neutralizing titers after one dose of BNT162b2SA compared to the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2, in the same individuals;Percentage of participants 12-15 years of age in Phase 3 reporting adverse events;Percentage of participants 12-15 years of age in Phase 3 reporting adverse events;Percentage of participants in Phase 1 reporting adverse events;Percentage of participants in Phase 1 reporting local reactions;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 2/3 reporting adverse events;Percentage of participants in Phase 2/3 reporting serious adverse events;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments

Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination;Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting local reactions;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting systemic events;In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting local reactions;In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting systemic events;In participants who receive a third dose of BNT162b2, percentage of participants reporting adverse events;In participants who receive a third dose of BNT162b2, percentage of participants reporting local reactions;In participants who receive a third dose of BNT162b2, percentage of participants reporting serious adverse events;In participants who receive a third dose of BNT162b2, percentage of participants reporting systemic events;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting adverse events;In participants, who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting local reactions;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting serious adverse events;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting systemic events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting local reactions;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting serious adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting systemic events;Noninferiority of the SARS-CoV-2 reference strain neutralizing titers after a third dose of BNT162b2 at 30 µg compared to after 2 doses of BNT162b2, in the same individuals;Noninferiority of the SARS-CoV-2 SA strain neutralizing titers after 2 doses of BNT162b2SA compared to the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2;Noninferiority of the SARS-CoV-2 SA strain neutralizing titers after one dose of BNT162b2SA compared to the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2, in the same individuals;Percentage of participants 12-15 years of age in Phase 3 reporting adverse events;Percentage of participants 12-15 years of age in Phase 3 reporting adverse events;Percentage of participants in Phase 1 reporting adverse events;Percentage of participants in Phase 1 reporting local reactions;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 2/3 reporting adverse events;Percentage of participants in Phase 2/3 reporting serious adverse events;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments

Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination;Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting local reactions;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting systemic events;In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting local reactions;In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting systemic events;In participants who receive a third dose of BNT162b2, percentage of participants reporting adverse events;In participants who receive a third dose of BNT162b2, percentage of participants reporting local reactions;In participants who receive a third dose of BNT162b2, percentage of participants reporting serious adverse events;In participants who receive a third dose of BNT162b2, percentage of participants reporting systemic events;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting adverse events;In participants, who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting local reactions;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting serious adverse events;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting systemic events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting local reactions;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting serious adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting systemic events;Noninferiority of the SARS-CoV-2 reference strain neutralizing titers after a third dose of BNT162b2 compared to after 2 doses of BNT162b2, in the same individuals;Noninferiority of the SARS-CoV-2 SA strain neutralizing titers after 2 doses of BNT162b2SA compared to the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2;Noninferiority of the SARS-CoV-2 SA strain neutralizing titers after one dose of BNT162b2SA compared to the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2, in the same individuals;Percentage of participants 12-15 years of age in Phase 3 reporting adverse events;Percentage of participants 12-15 years of age in Phase 3 reporting adverse events;Percentage of participants in Phase 1 reporting adverse events;Percentage of participants in Phase 1 reporting local reactions;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 2/3 reporting adverse events;Percentage of participants in Phase 2/3 reporting serious adverse events;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments

Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination;Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting local reactions;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting systemic events;In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting local reactions;In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting systemic events;In participants who receive a third dose of BNT162b2, percentage of participants reporting adverse events;In participants who receive a third dose of BNT162b2, percentage of participants reporting local reactions;In participants who receive a third dose of BNT162b2, percentage of participants reporting serious adverse events;In participants who receive a third dose of BNT162b2, percentage of participants reporting systemic events;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting adverse events;In participants, who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting local reactions;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting serious adverse events;In participants who receive BNT162b2SA given as 1 or 2 doses, percentage of participants reporting systemic events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting local reactions;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting serious adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting systemic events;Noninferiority of the SARS-CoV-2 reference strain neutralizing titers after a third dose of BNT162b2 compared to after 2 doses of BNT162b2, in the same individuals;Noninferiority of the SARS-CoV-2 SA strain neutralizing titers after 2 doses of BNT162b2SA compared to the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2;Noninferiority of the SARS-CoV-2 SA strain neutralizing titers after one dose of BNT162b2SA compared to the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2, in the same individuals;Percentage of participants 12-15 years of age in Phase 3 reporting adverse events;Percentage of participants 12-15 years of age in Phase 3 reporting adverse events;Percentage of participants in Phase 1 reporting adverse events;Percentage of participants in Phase 1 reporting local reactions;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 2/3 reporting adverse events;Percentage of participants in Phase 2/3 reporting serious adverse events;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments

Percentage of participants in Phase 1 reporting adverse events;Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination;Percentage of participants in Phase 2/3 reporting serious adverse events;Percentage of participants in Phase 2/3 reporting adverse events;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting systemic events;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting local reactions;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting serious adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting systemic events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting local reactions;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting systemic events;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting local reactions;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of participants 12-15 years of age in Phase 3 reporting adverse events;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of participants 12-15 years of age in Phase 3 reporting adverse events;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 1 reporting local reactions

Percentage of participants in Phase 1 reporting adverse events;Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination;Percentage of participants in Phase 2/3 reporting serious adverse events;Percentage of participants in Phase 2/3 reporting adverse events;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting systemic events;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting local reactions;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting serious adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting systemic events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting local reactions;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting systemic events;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting local reactions;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of participants 12-15 years of age in Phase 3 reporting adverse events;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of participants 12-15 years of age in Phase 3 reporting adverse events;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 1 reporting local reactions

Percentage of participants in Phase 2/3 reporting adverse events;Percentage of participants in Phase 1 reporting local reactions;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 1 reporting adverse events;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting local reactions;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting systemic events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting serious adverse events;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting local reactions;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting systemic events;Percentage of participants in Phase 2/3 reporting serious adverse events;Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination;Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination

Percentage of participants in Phase 2/3 reporting adverse events;Percentage of participants in Phase 1 reporting local reactions;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 1 reporting adverse events;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting local reactions;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting systemic events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting adverse events;In the first 360 participants randomized into Phase 2/3, percentage of participants reporting serious adverse events;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting local reactions;In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting systemic events;Percentage of participants in Phase 2/3 reporting serious adverse events;Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination;Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination